Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

globenewswire.com
FATE Listed as a key company in both the NK Cell Therapy Market and Pipeline, indicating its significant role and potential in the iPSC-derived NK cell space. INDP Appears in both NK Cell Therapy Market and Pipeline reports, suggesting it is a notable player in the development of iPSC-derived NK cell therapies. AMGN Listed as a key NK cell therapy company, but without specific details on its involvement in iPSC-derived NK cells, suggesting a general presence. NKTR Mentioned in the NK Cell Therapy Pipeline, but without specific details on its iPSC-derived NK cell focus, suggesting a general presence. IBIO Listed twice in the NK Cell Therapy Pipeline, but without specific details on iPSC-derived NK cells, suggesting a general presence in the broader NK cell therapy field. TAK Appears in the NK Cell Therapy Pipeline list, but without specific context on its iPSC-derived NK cell activities, indicating a general presence. SNY Mentioned in both NK Cell Therapy Pipeline and Rheumatoid Arthritis Pipeline, but without specific focus on iPSC-derived NK cells, indicating a general presence. INMB Appears in the NK Cell Therapy Pipeline list, but without specific context on its iPSC-derived NK cell activities, indicating a general presence. CLMT Appears in the NK Cell Therapy Pipeline list, but without specific context on its iPSC-derived NK cell activities, indicating a general presence. VERX VERAXA is mentioned in the NK Cell Therapy Pipeline, likely referring to Veru Inc. (VERX), but without specific details on iPSC-derived NK cells. GTBP Mentioned in the NK Cell Therapy Pipeline, but without specific details on iPSC-derived NK cells, suggesting a general presence. BHVN Mentioned in the NK Cell Therapy Pipeline, but without specific details on iPSC-derived NK cells, suggesting a general presence. CHRS Listed in the NK Cell Therapy Pipeline, but without specific details on iPSC-derived NK cells, suggesting a general presence. GSK Mentioned in both NK Cell Therapy Pipeline and Ovarian Cancer Pipeline, but without specific focus on iPSC-derived NK cells, indicating a general presence. BMY Mentioned in the Ovarian Cancer Pipeline, but without specific details on iPSC-derived NK cells, indicating a general presence. MRK Listed in the Ovarian Cancer Pipeline, but without specific details on iPSC-derived NK cells, indicating a general presence. ABBV Mentioned in both Ovarian Cancer Pipeline and Rheumatoid Arthritis Pipeline, but without specific focus on iPSC-derived NK cells, indicating a general presence. AZN Appears in both Ovarian Cancer Pipeline and Rheumatoid Arthritis Pipeline, but without specific context on its iPSC-derived NK cell activities, indicating a general presence. GILD Appears in the Rheumatoid Arthritis Pipeline list, but without specific context on its iPSC-derived NK cell activities, indicating a general presence. LLY Mentioned in the Rheumatoid Arthritis Pipeline, but without specific details on iPSC-derived NK cells, indicating a general presence. KYMR Listed in the Rheumatoid Arthritis Pipeline, but without specific details on iPSC-derived NK cells, suggesting a general presence. REGN Janssen Research & Development, LLC is part of Johnson & Johnson (JNJ), but Regeneron (REGN) is also a major player in the space and could be inferred. SPRY Appears in the Rheumatoid Arthritis Pipeline list, but without specific context on its iPSC-derived NK cell activities, indicating a general presence.

New York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'IPSC-derived NK Cells Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for IPSC-derived NK cells across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the IPSC-derived NK cells domain.

IPSC-derived NK Cells Clinical Trial Analysis Summary

Request a sample and discover the recent advances in IPSC-derived NK cells drugs @ https://www.delveinsight.com/sample-request/ipsc-derived-nk-cells-pipeline-insight?utm_source=globenewswire&utm_medium=pressrelease&utm_campaign=spr

What are IPSC-derived NK Cells?

Induced pluripotent stem cell (iPSC)–derived natural killer (NK) cells are immune effector cells generated by differentiating reprogrammed human somatic cells into NK cells under controlled laboratory conditions. These cells retain the innate cytotoxic properties of NK cells, including the ability to recognize and kill virus-infected or malignant cells without prior antigen sensitization. iPSC-derived NK cells offer key advantages over donor-derived NK cells, such as a renewable, standardized, and scalable “off-the-shelf” source with consistent phenotype and function. They can also be genetically engineered at the iPSC stage to enhance tumor targeting, persistence, or resistance to immunosuppressive tumor microenvironments, making them a promising platform for next-generation cancer immunotherapies.

Find out more about IPSC-derived NK cells drugs @ IPSC-derived NK Cells Treatment

A snapshot of the Pipeline IPSC-derived NK Cells Drugs mentioned in the report:

Learn more about the emerging IPSC-derived NK cells therapies @ IPSC-derived NK Cells Clinical Trials

Stuti Mahajan, consulting manager at DelveInsight, said iPSC-derived NK cells are poised to become a cornerstone of next-generation immunotherapy by overcoming key limitations of primary NK cells, including donor variability, limited scalability, and functional heterogeneity. Their clonal uniformity, inexhaustible supply, off-the-shelf manufacturability, and genetic engineering flexibility drive strong market momentum. With advancing clinical validation and maturing manufacturing and regulatory frameworks, iPSC-NK cells are expected to evolve from a promising innovation into a foundational, standardized, and broadly accessible modality in cancer immunotherapy.

Recent Developments in IPSC-derived NK Cells Treatment Space

Scope of the IPSC-derived NK Cells Pipeline Report

Dive deep into rich insights for new IPSC-derived NK cells treatments, visit @ IPSC-derived NK Cells Drugs

Table of Contents

For further information on the IPSC-derived NK cells cure research, reach out @ Medication for IPSC-derived NK Cells Treatment

Related Reports

NK Cell Therapy Market

NK Cell Therapy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NK cell therapy companies, including Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta Therapeutics, Senti Biosciences, among others.

NK Cell Therapy Clinical Trial Analysis

NK Cell Therapy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NK cell therapy companies, including Amgen, Innate Pharma, Nektar Therapeutics, SMT bio Co., Ltd., Alphageneron Pharmaceuticals, XNK Therapeutics, ImmunityBio, Cellid, Cantargia, Affimed Therapeutics, Takeda, Artiva Biotherapeutics, Sanofi, Dragonfly Therapeutics, INmune Bio, NKGen Biotech, Asclepius Technology Company Group, Glycostem Therapeutics (IPD Therapeutic), Wugen, Celularity, VERAXA, GamidaCell, MiNK Therapeutics, Indapta Therapeutics, ImmunityBio, Inc., Allife Medical Science and Technology, Nkarta, Base Therapeutics, GT Biopharma, Athenex, Ambicion, Biohaven Pharmaceuticals, Acepodia, Bright Path Biotherapeutics, Nkarta Therapeutics, Qihan Biotech, Century Therapeutics, Fate Therapeutics, Chimeric Therapeutics, Senti Biosciences, GICELL, Deverra Therapeutics, Medigen Biotechnology Corporation, GlaxoSmithKline, CytoImmune Therapeutics, Nuwacell Biotechnologies Co., Ltd., among others.

Rheumatoid Arthritis Clinical Trial Analysis

Rheumatoid Arthritis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key rheumatoid arthritis companies, including Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc., Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc., Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited., ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc., Candid Therapeutics, Inc., LAPIX Therapeutics, among others.

Ovarian Cancer Clinical Trial Analysis

Ovarian Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ovarian cancer companies, including Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-La Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics, among others.

Endometriosis Clinical Trial Analysis

Endometriosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Gedeon Richter, Changchun GeneScience Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ferring Pharmaceuticals, Chugai Pharmaceutical, Foraviset, EpicentRx, NETRIS Pharma, Maipl Therapeutics, Flightpath Biosciences, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.